Skip to main content

Recombinant Cynomolgus Monkey TREM2 Fc Chimera Protein, CF

Bio-Techne includes R&D Systems | Catalog # 10840-T2

Catalog #
Availability
Size / Price
Qty
Loading...
10840-T2-050

Key Product Details

Source

HEK293

Accession #

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived cynomolgus monkey TREM2 protein
Cynomolgus Monkey TREM2
(His19-Ser174)
Accession # XP_005553122.1
IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

His19

Predicted Molecular Mass

44 kDa

SDS-PAGE

55-65 kDa, under reducing conditions

Activity

Measured by its ability to bind fluorescein-conjugated E. coli Bioparticles.
The ED50 for this effect is 20.0-120 ng/mL.

Scientific Data Images for Recombinant Cynomolgus Monkey TREM2 Fc Chimera Protein, CF

Recombinant Cynomolgus Monkey TREM2 Fc Chimera SDS-PAGE.

2 μg/lane of Recombinant Cynomolgus Monkey TREM2 Fc Chimera (Catalog # 10840-T2) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 55-65 kDa and 110-130 kDa, respectively.

Recombinant Cynomolgus Monkey TREM2 Fc Chimera Binding Activity

Recombinant Cynomolgus Monkey TREM2 Fc Chimera Protein, CF (Catalog # 10840-T2) binds fluorescein-conjugated E. coli Bioparticles with an ED50 of 20.0-120 ng/mL.

Formulation, Preparation and Storage

10840-T2
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TREM2

Triggering Receptor Expressed on Myeloid cells-2 (TREM2) is a type I transmembrane member of the TREM subfamily within the much larger Ig superfamily. In humans, there are 7 TREM and TREM-like receptors which play important roles in the regulation of both innate and adaptive immune response (1). Mature cynomologus TREM2 consists of an extracellular domain (ECD) with one V-type Ig-like domain, a transmembrane domain with a conserved positively-charged lysine residue, and a short cytoplasmic tail (1). The ECD of Cynomologus TREM2 shares 97% amino acid identity with human TREM2. TREM2 is expressed on macrophages, immature myeloid dendritic cells, osteoclasts, microglia, and adipocytes (2-6). It promotes the differentiation and function of osteoclasts, the production of inflammatory cytokines by adipocytes, insulin resistance, and the phagocytic clearance of bacteria (6-8). TREM2 associates with the signaling adapter protein DAP12, both preferentially expressed in microglia, to modulate cytokine production (2). Additionally in the CNS, TREM2 binds to ApoE, ApoA1, and ApoB and mediates the clearance of apoptotic neurons, amyloid plaques, and cell debris following demyelination (3-5, 9). TREM2 also interacts with and modifies the signaling of Plexin A1 on dendritic cells and osteoclasts (10). Mutations in TREM2 or DAP12 are associated with the development of Alzheimer's disease and Nasu-Hakola disease (NHD/PLOSL) which is characterized by presenile dementia and bone cysts (11, 12). Soluble TREM2 is elevated in cerebrospinal fluid of patients with active multiple sclerosis (MS), and TREM2 blockade exacerbates disease symptoms in the experimental EAE model of MS (13, 14).

References

  1. Klesney-Tait, J. et al. (2006) Nat Immunol 7:1266.
  2. Turnbull, I.R. et al. (2006) J. Immunol. 177:3520.
  3. Takahashi, K. et al. (2005) J. Exp. Med. 201:647.
  4. Atagi, Y. et al. (2015) J. Biol. Chem. 290:26043.
  5. Wang, Y. et al. (2016) J. Exp. Med. 213:667.
  6. Cella, M. et al. (2003) J. Exp. Med. 198:645.
  7. Park, M. et al. (2015) Diabetes 64:117.
  8. N'Diaye, E-N. et al. (2009) J. Cell Biol. 184:215.
  9. Poliani, P.L. et al. (2015) J. Clin. Invest. 125:2161.
  10. Takegahara, N. et al. (2006) Nat. Cell Biol. 8:615.
  11. Colonna, M. and Y. Wang (2016) Nat. Rev. Neurosci. 17:201.
  12. Paloneva, J. et al. (2002) Am. J. Hum. Genet. 71:656.
  13. Piccio, L. et al. (2008) Brain 131:3081.
  14. Piccio, L. et al. (2007) Eur. J. Immunol. 37:1290.

Long Name

Triggering Receptor Expressed on Myeloid Cells 2

Alternate Names

PLOSL2, TREM-2

Entrez Gene IDs

54209 (Human); 102133279 (Cynomolgus Monkey)

Gene Symbol

TREM2

UniProt

Additional TREM2 Products

Product Documents for Recombinant Cynomolgus Monkey TREM2 Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Cynomolgus Monkey TREM2 Fc Chimera Protein, CF

For research use only

Loading...
Loading...